Reported 2 days ago
Bayer has secured a partnership with Cytokinetics to obtain rights for an experimental heart medication in Japan, further enhancing its cardiovascular business. The agreement includes an upfront payment of 50 million euros and potential contingent payments totaling up to 490 million euros based on development and sales milestones. This move comes as Bayer aims to strengthen its drug development pipeline amid various financial pressures.
Source: YAHOO